Targeting CD30 in anaplastic large cell lymphoma

Joseph Vadakara; Barbara Pro

doi:10.1007/s11899-012-0137-y

Targeting CD30 in anaplastic large cell lymphoma

Joseph Vadakara, Barbara Pro^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Anaplastic large cell lymphoma (ALCL) is a lymphoid neoplasm characterized by strong and uniform expression of the CD30 antigen on the cell surface. Current standard frontline therapy of ALCL is anthracycline-based combination chemotherapy, usually CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CHOPlike regimens. Despite aggressive chemotherapy a significant number of patients relapse. Newer agents and strategies are needed in the management of this challenging disease especially in ALK-negative and high-risk ALK-positive patients who tend to have a poor prognosis. In this review we discuss the different approaches to targeting CD30 including naked antibodies, "enhanced antibodies", antibody drug-toxin conjugates, radioimmunoconjugates, CD30-ligand-toxin conjugates, bispecific antibodies and T cellbased immune therapies.

Original language	English (US)
Pages (from-to)	285-291
Number of pages	7
Journal	Current Hematologic Malignancy Reports
Volume	7
Issue number	4
DOIs	https://doi.org/10.1007/s11899-012-0137-y
State	Published - Dec 1 2012

Keywords

Anaplastic large cell lymphoma
Brentuximab
CD30
MMAE
SGN-35
T-cell lymphoma
Vedotin

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1007/s11899-012-0137-y

Fingerprint Dive into the research topics of 'Targeting CD30 in anaplastic large cell lymphoma'. Together they form a unique fingerprint.

Cite this

@article{bafc5707f99f41e6a3be2a669082799c,

title = "Targeting CD30 in anaplastic large cell lymphoma",

abstract = "Anaplastic large cell lymphoma (ALCL) is a lymphoid neoplasm characterized by strong and uniform expression of the CD30 antigen on the cell surface. Current standard frontline therapy of ALCL is anthracycline-based combination chemotherapy, usually CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CHOPlike regimens. Despite aggressive chemotherapy a significant number of patients relapse. Newer agents and strategies are needed in the management of this challenging disease especially in ALK-negative and high-risk ALK-positive patients who tend to have a poor prognosis. In this review we discuss the different approaches to targeting CD30 including naked antibodies, {"}enhanced antibodies{"}, antibody drug-toxin conjugates, radioimmunoconjugates, CD30-ligand-toxin conjugates, bispecific antibodies and T cellbased immune therapies.",

keywords = "Anaplastic large cell lymphoma, Brentuximab, CD30, MMAE, SGN-35, T-cell lymphoma, Vedotin",

author = "Joseph Vadakara and Barbara Pro",

year = "2012",

month = dec,

day = "1",

doi = "10.1007/s11899-012-0137-y",

language = "English (US)",

volume = "7",

pages = "285--291",

journal = "Current Hematologic Malignancy Reports",

issn = "1558-8211",

publisher = "Springer Science + Business Media",

number = "4",

}

TY - JOUR

T1 - Targeting CD30 in anaplastic large cell lymphoma

AU - Vadakara, Joseph

AU - Pro, Barbara

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Anaplastic large cell lymphoma (ALCL) is a lymphoid neoplasm characterized by strong and uniform expression of the CD30 antigen on the cell surface. Current standard frontline therapy of ALCL is anthracycline-based combination chemotherapy, usually CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CHOPlike regimens. Despite aggressive chemotherapy a significant number of patients relapse. Newer agents and strategies are needed in the management of this challenging disease especially in ALK-negative and high-risk ALK-positive patients who tend to have a poor prognosis. In this review we discuss the different approaches to targeting CD30 including naked antibodies, "enhanced antibodies", antibody drug-toxin conjugates, radioimmunoconjugates, CD30-ligand-toxin conjugates, bispecific antibodies and T cellbased immune therapies.

AB - Anaplastic large cell lymphoma (ALCL) is a lymphoid neoplasm characterized by strong and uniform expression of the CD30 antigen on the cell surface. Current standard frontline therapy of ALCL is anthracycline-based combination chemotherapy, usually CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CHOPlike regimens. Despite aggressive chemotherapy a significant number of patients relapse. Newer agents and strategies are needed in the management of this challenging disease especially in ALK-negative and high-risk ALK-positive patients who tend to have a poor prognosis. In this review we discuss the different approaches to targeting CD30 including naked antibodies, "enhanced antibodies", antibody drug-toxin conjugates, radioimmunoconjugates, CD30-ligand-toxin conjugates, bispecific antibodies and T cellbased immune therapies.

KW - Anaplastic large cell lymphoma

KW - Brentuximab

KW - CD30

KW - MMAE

KW - SGN-35

KW - T-cell lymphoma

KW - Vedotin

UR - http://www.scopus.com/inward/record.url?scp=84872199040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872199040&partnerID=8YFLogxK

U2 - 10.1007/s11899-012-0137-y

DO - 10.1007/s11899-012-0137-y

M3 - Article

C2 - 23065407

AN - SCOPUS:84872199040

VL - 7

SP - 285

EP - 291

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 4

ER -

Targeting CD30 in anaplastic large cell lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this